NVCT
NASDAQ HealthcareNuvectis Pharma, Inc. - Common Stock
Biotechnology
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
�� 市场数据
| 价格 | $18.60 |
|---|---|
| 成交量 | 341,430 |
| 市值 | 586.37M |
| 贝塔系数 | -0.250 |
| RSI（14日） | 23.8 超卖 |
| 200日均线 | $9.27 |
| 50日均线 | $14.19 |
| 52周最高 | $29.27 |
| 52周最低 | $5.55 |
| Forward P/E | -19.38 |
| Price / Book | 34.70 |
🎯 投资策略评分
NVCT 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (49/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🎈 Over-Hyped (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 NVCT in your text
粘贴任何文章、记录或帖子 — 工具将提取 NVCT 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.